AIFA Doubles Down on Rare Disease Access: A New Era for Italian Patients
Italy’s Agenzia Italiana del Farmaco (AIFA) is reaffirming its commitment to tackling the challenges faced by individuals living with rare diseases. With over 2 million Italians and 30 million Europeans affected, the agency is focusing on faster diagnoses, equitable access to care, and innovative therapies. This renewed focus was highlighted during the recent Rare Disease Day celebrations on February 28th, with AIFA headquarters illuminated as a symbol of solidarity.
The Diagnostic Odyssey: A Critical Bottleneck
A significant hurdle for rare disease patients is the lengthy time it takes to receive a diagnosis. On average, it can take over four years to pinpoint the cause of symptoms, a delay that profoundly impacts quality of life. AIFA recognizes this and is prioritizing initiatives to streamline diagnostic pathways and connect patients with specialized centers.
New Therapies on the Horizon: Duvyzat, Carvykti, and Beyond
Recent approvals signal a positive shift in treatment options. AIFA has recently established reimbursement for two innovative drugs: Duvyzat for Duchenne muscular dystrophy and Carvykti, the first CAR-T cell therapy authorized for multiple myeloma. These advancements represent a significant step forward in addressing previously unmet clinical needs.
the European Medicines Agency (EMA) approved 16 orphan drugs in 2025, demonstrating a growing pipeline of potential treatments. Emerging therapies include a gene therapy for Wiskott-Aldrich syndrome, a rare immune deficiency, and a topical gene therapy for epidermolysis bullosa dystrophica, a severe genetic skin condition. An antibody monoclonale for Graves’ ophthalmopathy, a rare autoimmune eye disease, also offers new hope for patients.
Beyond Treatment: A Holistic Approach to Rare Disease Care
AIFA’s commitment extends beyond simply approving new drugs. The agency is actively working to improve the organization of care pathways, ensuring sustainable access to treatment, and upholding the right to health for all individuals with rare diseases. “The rarity of a pathology cannot translate into invisibility,” stated AIFA President Robert Nisticò.
The Role of Innovation: A Global Perspective
Over 30% of the global research and development pipeline is now focused on rare disease treatments, representing 7,721 projects worldwide. This surge in innovation is fueled by a growing understanding of the genetic and molecular basis of these conditions, paving the way for targeted therapies.
Did you know?
The term “orphan drugs” refers to medications developed to treat rare diseases, often affecting fewer than 200,000 people in the United States. Incentives are often provided to pharmaceutical companies to encourage the development of these drugs, as they may not be commercially viable without support.
Frequently Asked Questions
Q: What is AIFA’s role in rare disease treatment?
A: AIFA is the Italian agency responsible for regulating pharmaceuticals and ensuring access to therapies, including those for rare diseases.
Q: How long does it typically take to diagnose a rare disease?
A: On average, it takes over four years to receive a diagnosis for a rare disease.
Q: What are orphan drugs?
A: Orphan drugs are medications developed to treat rare diseases.
Q: What is CAR-T cell therapy?
A: CAR-T cell therapy is a type of immunotherapy that uses a patient’s own immune cells to fight cancer.
Q: What is the significance of illuminating AIFA headquarters?
A: It’s a symbolic gesture to raise awareness and demonstrate AIFA’s commitment to rare disease patients.
Pro Tip: If you or a loved one is experiencing symptoms of a rare disease, advocate for thorough testing and seek a second opinion from a specialist.
Learn more about rare diseases and available resources at National Organization for Rare Disorders (NORD).
Have questions about rare disease access in Italy? Share your thoughts in the comments below!
